omeprazole has been researched along with Kahler Disease in 3 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19." | 9.14 | Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ( Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L, 2009) |
| "Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19." | 5.14 | Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ( Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L, 2009) |
| " Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM)." | 4.88 | Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. ( Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canitano, A | 1 |
| Iessi, E | 1 |
| Spugnini, EP | 1 |
| Federici, C | 1 |
| Fais, S | 1 |
| Quinn, DI | 1 |
| Nemunaitis, J | 1 |
| Fuloria, J | 1 |
| Britten, CD | 1 |
| Gabrail, N | 1 |
| Yee, L | 1 |
| Acharya, M | 1 |
| Chan, K | 1 |
| Cohen, N | 1 |
| Dudov, A | 1 |
| Vilas-Boas, F | 1 |
| Gonçalves, R | 1 |
| Sobrinho Simões, M | 1 |
| Lopes, J | 1 |
| Macedo, G | 1 |
1 review available for omeprazole and Kahler Disease
| Article | Year |
|---|---|
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induc | 2012 |
1 trial available for omeprazole and Kahler Disease
| Article | Year |
|---|---|
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bor | 2009 |
1 other study available for omeprazole and Kahler Disease
| Article | Year |
|---|---|
Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship | 2016 |